



Atul Ltd

Atul 396 020, Gujarat, India
legal@atul.co.in | www.atul.co.in
(+91 2632) 230000

August 09, 2024

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Through: BSE Listing portal
Scrip code: 500027

The Manager
Listing Department
National Stock Exchange of India Limited
“Exchange Plaza” C – 1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
Through: NEAPS
Symbol: ATUL

Dear Sir,

Sub: Update on the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) – Press release

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Regulations”), we inform you that Atul Bioscience Ltd, a 100% subsidiary of the Company has received the **Establishment Inspection Report (EIR)** from the **the United States Food and Drug Administration** for its manufacturing facility at Ambernath, Maharashtra.

A press release in this regard is enclosed.

We request you to inform the members of the exchange accordingly.

Thank you,

Yours faithfully
For Atul Limited

Lalit Patni
Company Secretary and
Chief Compliance Officer

Registered office: Atul House, G I Patel Marg, Ahmedabad 380 014, Gujarat, India
CIN: L99999GJ1975PLC002859



Lalbai Group



Atul Bioscience Ltd

N-37, Additional Ambernath Industrial Area, MIDC, Anand Nagar
MMR Zone-II, Ambernath (East) 421 506, Maharashtra, India
pharma@atul.co.in | (+91 251) 2621667 | www.atulbio.co.in

Press Release

Atul Bioscience Ltd received EIR from the US FDA for its Ambernath facility

Mumbai, August 09, 2024: Atul Bioscience Ltd (ABL), a 100% subsidiary of Atul Ltd, received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility situated in Ambernath, Maharashtra. The EIR was issued post the last inspection of the facility conducted from May 06, 2024, to May 10, 2024 which concluded with **zero FDA 483 observations**. The Company is engaged in manufacturing and marketing of active pharmaceutical ingredients (APIs), their intermediates and contract manufacturing operations.

Commenting on this achievement, Dr Prabhakar Chebiyyam, Managing Director of ABL, said, "This is a significant milestone for our Company and a testament to our commitment to maintaining quality, safety and compliance in our manufacturing processes." He further added, "The successful completion of this inspection reflects the dedication and hard work of our entire team. It strengthens our resolve to deliver high-quality pharmaceutical products consistently and further improve our processes to meet the ever-evolving needs of the global pharmaceutical industry."

About ABL

ABL is engaged in the manufacturing and marketing of APIs and their intermediates for different therapeutic areas, particularly antiasthmatic, antidepressant, antidiabetic, antifungal, anti-infective, anti-inflammatory, antineoplastic, antiretroviral and cardiovascular, as well as contract manufacturing operations. It has plants located at Atul in Gujarat and Ambernath in Maharashtra.

Contact

For more information, please visit www.atulbio.co.in or write to us at pharma@atul.co.in

Marketing office: Floor 15, C Wing, Lotus Corporate Park, Western Express Highway, Goregaon (East)

Mumbai 400 063 Maharashtra, India | (+91 22) 62505200

Registered office: D-1, Riverside Colony 2, Atul 396 020, Gujarat, India

CIN: U24230GJ1997PLC032369



Lalbai Group